Akademik Veri Yönetim Sistemi
ISTANBUL MEDICAL JOURNAL, cilt.23, sa.3, ss.174-178, 2022 (ESCI, TRDizin)
Introduction: In this study, the aim was to investigate smoking cessation on peak nasal inspiratory flow (PNIF) and nasal mucociliary clearance (MCC). Methods: Sixty-two (32 male and 30 female) smokers were included in this prospective study. Varenicline (Champix"), R-Pharm, Germany) was prescribed to all subjects who want to quit smoking as supportive therapy. Three-month treatment is planned. Day 0 (baseline), 3rd month (after smoking cessation), and 6 h (3 months after smoking cessation) PNIF values with decongestant (PNIFwD) and without decongestant (PNIFsD) and nasal mucociliary clearance time (MCT) with the saccharine test were determined. The acquired data were evaluated statistically. Results: The mean age of the subjects was 36.77 +/- 9.63 (minimum: 18, maximum: 60) years. Significant differences were found between the PNIF and MCT values during different study periods (p<0.05). The medians of nasal MCT values for the 3rd and 6th months were significantly lower than the median of baseline values (p<0.05). Additionally, the median of nasal MCT values for the 6th month was significantly lower than the median of nasal MCT values for the 3rd month (p=0.0003, p<0.05). The medians of PNIFsD values for the 3rd and 6th months were significantly higher than the median of baseline values (p<0.05). Additionally, the median of the 6th -month values was significantly higher than the median of the 3rd-month values (p=0.023, p<0.05). There was no significant difference in terms of PNIFwD evaluations (p=0.06, p>0.05). Conclusion: The results of this study showed that smoking cessation improves nasal MCC and airflow.